Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2020-09-14 Capital/Financing Update
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an underwritten public offering of common stock and Series D Convertible Preferred Stock, including details about the underwriting agreement, terms of the offering, and the designation of new preferred stock. It also includes a press release about pricing the offering and forward-looking statements. There are no financial statements or detailed financial performance data included, nor is this an annual or quarterly report. The primary focus is on the company's financing activity and capital raising. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement. Hence, the classification is CAP with high confidence.
2020-09-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, describing an offering of common stock and Series D Convertible Preferred Stock. It includes detailed information about the securities offered, underwriting, risk factors, use of proceeds, and other offering-related disclosures. This type of document is a capital raising filing related to financing activities, specifically a prospectus supplement for a securities offering. It is not an annual or quarterly report, earnings release, management discussion, or any other report type. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement but the actual offering document.
2020-09-14 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-10 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of common stock and Series D Convertible Preferred Stock. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and other offering details. This type of document is a capital raising disclosure and is not a financial report, earnings release, or management discussion. It is a formal offering document used to inform investors about a securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a brief notice, confirming it is the actual offering document rather than a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2020-09-09 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 9, 2020, by Spero Therapeutics, Inc. The content describes the termination of an "At-the-Market" Offering Prospectus Supplement related to a Controlled Equity Offering Sales Agreement. It details the cessation of sales under the ATM Offering and states that the Sales Agreement remains in effect. This is an update on the company's capital raising activities and changes to its financing arrangements. The document is not a full financial report, earnings release, or management discussion, but rather a specific update on financing activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3611 characters, which is consistent with a typical 8-K filing for such an event, not a full report or announcement of a report publication.
2020-09-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a Regulation FD Disclosure about positive topline results from a Phase 3 clinical trial and an investor presentation, both attached as exhibits. It also includes a press release and forward-looking statements. There are no detailed financial statements or comprehensive financial analysis typical of an earnings release or annual/interim report. The document primarily announces clinical trial results and related investor materials, which are attached as exhibits. The length is over 10,000 characters, so it is not a brief announcement. However, the Form 8-K itself is a regulatory filing used to disclose material events and is not a full financial report or earnings release. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like ER or IP.
2020-09-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.